---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-018867"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2026-04-24T23:59:59+00:00"
generated_at: "2026-05-15T04:16:23.705995+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals completes acquisition of TELI, consolidating global rights to Telomir-1

## Summary
- Acquired 100% of TELI for 34,389,710 restricted shares of Telomir common stock to former TELI shareholders.
- Bayshore Trust contributed $1 million at closing and has an option to provide up to $4 million upon IND acceptance and Phase 1/2 study start.
- Option includes $2 million for 1,492,537 shares at $1.34 per share upon FDA IND acceptance, and another $2 million for the same number of shares upon Phase 1/2 initiation.
- Transaction eliminates prior geographic fragmentation, giving Telomir full worldwide control of Telomir-1 development and commercialization.

## SEC filing metadata
- accession: 0001493152-26-018867
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2026-04-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/0001493152-26-018867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-018867
- JSON: https://secwatch.observer/filing/0001493152-26-018867.json
- Plain text: https://secwatch.observer/filing/0001493152-26-018867.txt

## Key facts
- M&A Transactions
  Telomir Pharmaceuticals, Inc. completed an acquisition involving TELI Pharmaceuticals, Inc. for 34,389,710 restricted shares of the Company’s common stock (closed 2026-04-22).
  - Action: acquisition
  - Counterparty: TELI Pharmaceuticals, Inc.
  - Consideration: 34,389,710 restricted shares of the Company’s common stock
  - Closing: 2026-04-22
  source text: by the Company’s shareholders during the Company’s annual shareholders meeting on March 23, 2026. At closing, the Company acquired 100% of TELI in exchange for a total of 34,389,710 restricted shares of the Company’s common stock, no par value issued to TELI’s former shareholders (the “Shares”). The number of shares issued was determined based on an exchange
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/0001493152-26-018867-index.htm
- Material Agreements
  Telomir Pharmaceuticals, Inc. entered into Commitment Agreement with Bayshore Trust (effective 2026-04-22).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Bayshore Trust
  - Effective: 2026-04-22
  source text: On April 22, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) completed its acquisition of TELI Pharmaceuticals, Inc. (“TELI”) pursuant to the previously announced merger agreement (the “Transaction”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/0001493152-26-018867-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.